About
Dr. Emir Sandhu joined Sandbox in 2019 and is a Partner at Sandbox Industries, a Managing Director at the Blue Venture Fund, and co-founded the Sandbox Clinical Ventures Fund. He currently serves on the board of directors of Somatus, Onc.AI, and Ultromics. He serves as a Board Observer of Network Bio. He was previously a board director of Limber Health (Acquired by Net Health), Exai Bio (Acquired by Network Bio), and a Board Observer of Noctrix Health (Acquired by ResMed). He also supports or has supported the Blue Venture Fund's investments in Thrive Earlier Detection (Acquired by Exact Sciences), HeartFlow (NASDAQ: HTFL), and PicassoMD.
Dr. Sandhu focuses on investments from seed to buyout within healthcare services and medical technologies, including devices, diagnostics, and AI.
Prior to joining Sandbox, Dr. Sandhu consulted on medical innovation initiatives at Google and co-founded OpenBiome, which supports research on the human microbiome and has treated patients suffering from C. difficile infection.
Dr. Sandhu holds an MD from Harvard Medical School, an MBA from Harvard Business School and a BA in Economics from the University of North Carolina as a Morehead-Cain Scholar.
Dr. Sandhu completed his medical residency in Diagnostic Radiology at Stanford University and Memorial Sloan Kettering Cancer Center. He served as adjunct faculty at Stanford.
He lives in the San Francisco Bay Area and enjoys golfing.
